title: Proteomics of gliomas: initial biomarker discovery and evolution of technology.
abstract: Gliomas are a group of aggressive brain tumors that diffusely infiltrate adjacent brain tissues, rendering them largely incurable, even with multiple treatment modalities and agents. Mostly asymptomatic at early stages, they present in several subtypes with astrocytic or oligodendrocytic features and invariably progress to malignant forms. Gliomas are difficult to classify precisely because of interobserver variability during histopathologic grading. Identifying biological signatures of each glioma subtype through protein biomarker profiling of tumor or tumor-proximal fluids is therefore of high priority. Such profiling not only may provide clues regarding tumor classification but may identify clinical biomarkers and pathologic targets for the development of personalized treatments. In the past decade, differential proteomic profiling techniques have utilized tumor, cerebrospinal fluid, and plasma from glioma patients to identify the first candidate diagnostic, prognostic, predictive, and therapeutic response markers, highlighting the potential for glioma biomarker discovery. The number of markers identified, however, has been limited, their reproducibility between studies is unclear, and none have been validated for clinical use. Recent technological advancements in methodologies for high-throughput profiling, which provide easy access, rapid screening, low sample consumption, and accurate protein identification, are anticipated to accelerate brain tumor biomarker discovery. Reliable tools for biomarker verification forecast translation of the biomarkers into clinical diagnostics in the foreseeable future. Herein we update the reader on the recent trends and directions in glioma proteomics, including key findings and established and emerging technologies for analysis, together with challenges we are still facing in identifying and verifying potential glioma biomarkers.
authors.affiliation: Laboratory of Molecular Neuro-Oncology, Departments of Neurosurgery, Hematology and Medical Oncology, School of Medicine, and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
authors.forename: Juliya
authors.initials: J
authors.lastname: Kalinina
authors.forename: Junmin
authors.initials: J
authors.lastname: Peng
authors.forename: James C
authors.initials: JC
authors.lastname: Ritchie
authors.forename: Erwin G
authors.initials: EG
authors.lastname: Van Meir
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis* / Q000378:metabolism; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D005910:Glioma / Q000175:diagnosis* / Q000378:metabolism; D006801:Humans; D040901:Proteomics / Q000295:instrumentation* / Q000379:methods*
chemical_list: D014408:Biomarkers, Tumor